Daily Brief China: Regencell Bioscience Holdings, Xiaomi Corp, Ares Management and more

In today’s briefing:

Is This Chinese Biotech Going Out of Business?
Lucror Analytics – Morning Views Asia
Asia Real Estate Tracker (04-Apr-2025): JD Property buying Brisbane estate for $153M.

Is This Chinese Biotech Going Out of Business?

This Nasdaq-listed, Hong Kong-based company hopes to apply Traditional Chinese Medicine (TCM) to significant illnesses like ADHD, but that seems unlikely. The company is a family affair, with all research provided by the CEO’s father, so one wonders how objective scientific assessment can be.
The stock surged by more than 700% in a month without patent approval, a buyout offer, or other notable news. The CEO funded a share buyback, but rather than demonstrating faith in the company, the repurchase looked suspiciously like a way to inflate the short-term share price, possibly for an equity issue or insider self- enrichment since the CEO’s compensation is tied to market capitalization.
This is a highly speculative business run by a family team from Hong Kong, thus little trusted in the U.S. and very volatile.

In the US, the ISM services index declined to 50.8 (52.9 e / 53.5 p) in March 2025, the lowest level since June 2024, albeit remaining in expansion territory for the ninth consecutive month.
Meanwhile, the March 2025 final S&P services PMI climbed to 54.4 (54.2 e / 51.0 p), but was stable compared to the preliminary reading of 54.3.
The composite PMI rose to 53.5 (53.5 e / 51.6 p). Separately, the trade deficit narrowed to USD 122.7 bn (USD 123.5 bn e / USD 130.7 bn revised p) in February.

JD Property is acquiring Brisbane estate from ESR JV for $153M, expanding their real estate portfolio in Australia.
M&G and Nuveen have appointed new global real estate heads, signaling strategic leadership changes within their respective companies.
GLP completes a $360M China data center fund, highlighting their continued investment in the growing data center market in China. Warburg Pincus acquires Tokyo office building through Life Sciences JV with Eastgate, further expanding their real estate holdings in Asia.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network